60 Degrees Pharmaceuticals Expands ARAKODA Sales Strategy Following Positive Commercial Pilot Results
核心洞察
60 Degrees Pharmaceuticals (搜索) reported encouraging results from a 6-month commercial pilot that demonstrated increasing demand for ARAKODA among prescribers and overall product sales growth.
The company plans to double its inside sales team, partner with GoodRx (搜索) for broader patient access, and enhance digital marketing campaigns to accelerate ARAKODA sales in 2026.
Following FDA feedback on its breakthrough therapy designation request for babesiosis (搜索), the company will add at least two clinical sites to ongoing babesiosis treatment trials.
60 Degrees Pharmaceuticals (搜索) announced plans to significantly expand its sales and marketing efforts for ARAKODA (tafenoquine) following encouraging results from a 6-month commercial pilot that demonstrated increasing demand among prescribers and overall product sales growth. The company will implement several strategic initiatives in 2026 to capitalize on the growing market interest in its malaria (搜索) prevention medication.
Commercial Expansion Strategy
The expansion plan centers on three key initiatives designed to broaden market reach and accelerate ARAKODA sales. The company will double its inside sales team to deepen outreach across prescribers, strengthen provider relationships, and enhance product education and support. Additionally, 60 Degrees Pharmaceuticals (搜索) will partner with GoodRx (搜索) to provide wider coverage of its point-of-sale ARAKODA offer, enabling patients and prescribers to access savings information more efficiently.
The company will also continue optimizing its integrated digital marketing campaign, described as a "surround sound" approach that ensures high-frequency awareness, relevant targeting, and sustained engagement across prescriber audiences.
"Results of our commercial pilot intended to measure market demand among prescribers demonstrated increasing demand trends," said Chief Executive Officer Geoff Dow, PhD. "The investments we plan for 2026 reflect our commitment to expand reach, improve access, and support healthcare providers and patients with what we consider to be best-in-class malaria (搜索) prevention."
Babesiosis Clinical Development Progress
In parallel with its commercial expansion, 60 Degrees Pharmaceuticals (搜索) will add at least two babesiosis (搜索) clinical sites for its ongoing trials following recent FDA feedback. The company is conducting a randomized placebo-controlled study in hospitalized babesiosis patients (NCT06207370) and an expanded access study in high-risk patients with treatment refractory relapsing disease (NCT06478641).
The FDA recently declined the company's request for Breakthrough Therapy Designation for babesiosis (搜索) treatment but acknowledged that babesiosis meets the criteria for being classified as a serious or life-threatening disease or condition. The agency suggested that 60 Degrees Pharmaceuticals (搜索) resubmit its request with data from ongoing controlled clinical trials for babesiosis treatment. The additional clinical sites may increase the likelihood of enrolling patients on a more condensed timeline.
ARAKODA Product Profile
ARAKODA (tafenoquine) is approved for malaria (搜索) prophylaxis in the United States and was originally discovered by Walter Reed Army Institute of Research. The drug received FDA approval in 2018 and was commercially launched in 2019 in both the United States and Australia, where it is marketed as KODATEF.
According to the Centers for Disease Control and Prevention, tafenoquine's long terminal half-life of approximately 16 days may offer potential advantages in less-frequent dosing for malaria (搜索) prophylaxis. The safety of the approved regimen has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months.
The prescribed regimen involves 2 x 100 mg tablets once daily for three days prior to travel to malaria (搜索)-endemic areas, followed by 2 x 100 mg tablets weekly for up to six months during travel, and a final 2 x 100 mg dose in the week following travel.
Safety Considerations
ARAKODA carries important safety warnings, including mandatory G6PD testing before prescribing due to the risk of hemolytic anemia (搜索) in patients with glucose-6-phosphate dehydrogenase (搜索) deficiency. The drug is contraindicated in patients with G6PD deficiency, those with a history of psychotic disorders, and during breastfeeding when the infant's G6PD status is deficient or unknown.
The most common adverse reactions include headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase, motion sickness, insomnia, depression, abnormal dreams, and anxiety. Due to the drug's long half-life, adverse reactions may be delayed in onset and duration.
Tafenoquine has not been proven effective for treatment or prevention of babesiosis (搜索) and is not approved by the FDA for such indication, though the company's ongoing clinical trials are investigating its potential in this area.